Retatrutide Dosing Protocol — Phase 2 Schedule, Vial Math, and Storage

Most "retatrutide dosing" content online either guesses or extrapolates from semaglutide. Neither is useful. Eli Lilly's phase 2 trial (Jastreboff et al., NEJM 2023) published a specific titration schedule with specific dose arms — and that's the only retatrutide dosing protocol with published human safety and efficacy data. Here it is, with the vial math and storage notes researchers actually need.

1. The Jastreboff 2023 NEJM phase 2 schedule

The retatrutide phase 2 trial published in New England Journal of Medicine in June 2023 is the most-cited reference for retatrutide dosing. It tested four target dose arms in adults with obesity over 48 weeks, all using once-weekly subcutaneous injection.

The 12 mg arm achieved the headline 24.2% mean weight reduction at 48 weeks. The titration design — quadrupling over 12 weeks before hitting target — was explicitly designed to manage GI side effects (nausea, vomiting, diarrhoea) which are the dose-limiting factor for incretin agonists generally and triple agonists specifically. Skipping or compressing the titration schedule is the most reliable way to trigger intolerable GI symptoms.

2. Why retatrutide titration matters more than semaglutide titration

Retatrutide is a triple agonist — it activates GLP-1, GIP, and the glucagon receptor in one molecule. Semaglutide hits only GLP-1. The glucagon-receptor arm of retatrutide is the new mechanism, and it's the one driving the unusually high weight reduction. It also contributes to early-titration nausea in a way semaglutide doesn't.

In the 12 mg arm of Jastreboff 2023, the rate of GI adverse events was meaningfully higher in weeks 1-8 than at maintenance dose. The literature reading is consistent: tolerance to the glucagon-arm GI signal develops over weeks, not days. Researchers running comparison protocols against semaglutide and tirzepatide usually need a longer titration window than they would for either.

3. Vial reconstitution math — 5 mg vs 10 mg

REVIVE LAB UAE supplies retatrutide in two vial sizes: 5 mg and 10 mg lyophilised peptide. Both arrive as off-white powder, sealed under inert gas. Reconstitution with bacteriostatic water UAE is straightforward, but the per-unit math differs:

The practical sweet spot for the 12 mg arm titration (covering 2 mg through 12 mg) is the 10 mg vial reconstituted with 2 mL bac water — 5 mg/mL — because every dose in the titration falls into a clean U-100 insulin syringe volume between 20 and 240 units, all readable at 1-unit precision. For protocols staying at or below 4 mg, the 5 mg vial with 1 mL bac water works fine.

4. Storage — lyophilised vs reconstituted

Unreconstituted retatrutide is highly stable. The lyophilised peptide tolerates room temperature for short windows (the entire UAE same-day delivery window from REVIVE LAB falls inside that envelope) and is rated stable for 24+ months refrigerated at 2-8 °C. Once reconstituted with bacteriostatic water, the stability window shortens considerably:

• Refrigerated (2-8 °C): 28 days is the commonly cited stability window for reconstituted GLP-1 / GIP / glucagon-receptor analogues. Most peptide chemistry references support this.
• Room temperature: Not recommended beyond brief handling — bac water provides bacteriostatic protection, not thermal stability.
• Freezer (-20 °C): Possible but freeze-thaw cycles damage peptide integrity. Avoid unless you're committing to a single thaw.
• Light exposure: Store vials in original boxes — peptides are photolabile.

For UAE researchers, the relevant detail is summer ambient: outdoor temperatures of 45 °C+ from June through September. REVIVE LAB ships in insulated packaging with cold-pack inserts, and we recommend transferring vials to refrigeration on arrival even though the lyophilised form is more thermally tolerant than the reconstituted form. See our dedicated post on UAE peptide cold-chain shipping for the full thermal-stability literature.

5. Injection site and rotation

Subcutaneous injection sites used in the phase 2 trial were the abdomen, thigh, and upper arm — standard sites for slow-absorbing weekly peptides. Site rotation is standard practice to avoid lipohypertrophy. Insulin pen needles (4-6 mm, 31-32 G) or insulin syringes (29-31 G) are appropriate; the volumes involved are small enough that needle gauge dominates over barrel size.

6. What the phase 2 trial did not test

The Jastreboff 2023 dataset is one phase 2 trial in adults with obesity. It is not a comprehensive safety database. Things the trial did not cover that researchers asking about retatrutide should know:

• Longer than 48 weeks. Phase 3 (the TRIUMPH program) is in progress as of this writing. Multi-year data is not yet published.
• Non-obese populations. Phase 2 enrolled BMI ≥30 (or ≥27 with comorbidities). Effects at lower BMI ranges are not characterised.
• Stack interactions. Co-administration with GHRH analogues like Tesamorelin (research interest for body recomp) is anecdotal at this stage. No controlled trial data exists for the combination.
• Dose discontinuation rebound. Several semaglutide datasets (STEP-4 trial extension) show substantial weight regain on cessation. Retatrutide discontinuation has not been formally studied at the published level.

7. UAE supply context — why the vial size matters here

UAE researchers running comparison protocols against compounded semaglutide face a specific supply problem: most compounded GLP-1 in the regional grey market is reconstituted at variable concentrations, with no batch-level COA. Retatrutide from REVIVE LAB UAE arrives lyophilised with HPLC-verified mass and an accompanying lot-level certificate of analysis — meaning the dose-response data above can be reproduced with confidence.

For protocols running the full 12 mg titration arm, the 10 mg vial is the more efficient choice. For shorter protocols or 4 mg-arm comparisons, the 5 mg vial is the economical pick. Both are available as retatrutide UAE with same-day Dubai dispatch and 24-hour delivery across the seven emirates.

8. The summary

• Retatrutide dosing protocol comes from Jastreboff 2023 NEJM phase 2 — once-weekly SC, titration over 12 weeks to target of 1, 4, 8, or 12 mg.
• Titration is non-optional — the glucagon-arm GI signal needs weeks of tolerance development.
• 5 mg vial + 2 mL bac water = 2.5 mg/mL; 10 mg vial + 2 mL = 5 mg/mL.
• Refrigerate reconstituted vials at 2-8 °C, use within 28 days. Avoid freeze-thaw.
• UAE supply: REVIVE LAB UAE ships HPLC-verified retatrutide in both vial sizes with lot-level COA, same-day dispatch before 3 PM, 24-hour delivery.